Samplix and the EIC Accelerator: Single Cells, Deep Losses

Samplix, based in Birkerød north of Copenhagen, makes Xdrop, a system that wraps single living cells in stable double-emulsion droplets so that standard flow cytometers and sorters can measure what each cell does, such as releasing cancer-killing molecules or antibodies. It was selected in the EIC Accelerator's January 2023 cut-off for blended finance and received an EU grant of €2.50 million for Cellularity, a €4.93 million project that ran from August 2023 to July 2025, according to CORDIS.

The project is closed. Its final report lists a new instrument, Xdrop Plus, two new microfluidic cartridges and a process that handles eight samples in five minutes, according to the CORDIS reporting page. Samplix's 2025 annual report says the project "played a key role in finalising the products and applications that are now being commercially marketed". The same report shows a gross loss of DKK 659,163, a net loss of DKK 55.5 million and negative equity of DKK 114.3 million, and its auditor draws attention to "a material uncertainty which may give rise to considerable doubt" about whether the company can continue, according to filings with the Danish Business Authority.

Where Samplix Stands Now

Samplix has no binding agreement for new funding. "No binding agreement has been entered with the shareholders or other regarding additional funds to the continued operations," its 2025 accounts state, adding that management expects to obtain liquidity from existing and new shareholders. A new chief executive, Henrik Martin Pfundheller, joined in February 2026. The company says it has strengthened commercial collaborations with Sony, started joint marketing with Bio-Rad, and placed instruments with key opinion leaders, expecting several publications to be submitted in 2026.

The Technology: One Cell, One Droplet

Instead of building an expensive dedicated machine, Samplix prepares droplets that run on instruments most labs already own. Immune cells can be paired with cancer cells in a droplet to test their killing power, and millions of antibody-producing cells can be screened to find rare ones. The final report claims at least ten times the capacity of existing systems at roughly one tenth of the cost; no independent comparison has been published.

What the EIC Award Promised, and What the Record Shows

The award promised the shift to single-cell formats in functional analyses of living cells. The final report and the annual report agree that the platform, cartridges, protocols and software were completed and put on sale. What followed is weaker: gross profit fell from DKK 11.0 million in 2024 to a loss in 2025.

1. New instrumentDeliveredXdrop Plus.
2. New cartridgesDeliveredDE20 and DE50.
3. Commercial launchDeliveredMarketed, per 2025 report.
4. Sales growthMissedGross loss in 2025.

The Money

Samplix lost DKK 207 million over 2021 to 2025. Its negative equity is carried by debt: DKK 81.4 million in convertible and profit-sharing loans, DKK 31.3 million in other long-term payables and DKK 35.9 million in other short-term payables at the end of 2025. External lenders hold a USD 500,000 mortgage deed secured on its patents. Whether the EIC Fund invested the equity part of the blended finance award is not stated in the accounts.

What Cannot Be Checked

Why Europe Should Care

Single-cell functional data feeds cell therapies, antibody discovery and AI models for drug design, the uses Samplix names in its reports. Samplix finished a European alternative that it says is cheaper, with EU help, but the company that owns it is running on debt and has no committed funding.

The Verdict

Samplix and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.